Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark : an observational cohort study. / Bager, Peter; Wohlfahrt, Jan; Fonager, Jannik; Rasmussen, Morten; Albertsen, Mads; Michaelsen, Thomas Yssing; Møller, Camilla Holten; Ethelberg, Steen; Legarth, Rebecca; Button, Mia Sarah Fischer; Gubbels, Sophie; Voldstedlund, Marianne; Mølbak, Kåre; Skov, Robert Leo; Fomsgaard, Anders; Krause, Tyra Grove; The Danish Covid-19 Genome Consortium.

I: The Lancet Infectious Diseases, Bind 21, Nr. 11, 2021, s. 1507-1517.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Bager, P, Wohlfahrt, J, Fonager, J, Rasmussen, M, Albertsen, M, Michaelsen, TY, Møller, CH, Ethelberg, S, Legarth, R, Button, MSF, Gubbels, S, Voldstedlund, M, Mølbak, K, Skov, RL, Fomsgaard, A, Krause, TG & The Danish Covid-19 Genome Consortium 2021, 'Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study', The Lancet Infectious Diseases, bind 21, nr. 11, s. 1507-1517. https://doi.org/10.1016/S1473-3099(21)00290-5

APA

Bager, P., Wohlfahrt, J., Fonager, J., Rasmussen, M., Albertsen, M., Michaelsen, T. Y., Møller, C. H., Ethelberg, S., Legarth, R., Button, M. S. F., Gubbels, S., Voldstedlund, M., Mølbak, K., Skov, R. L., Fomsgaard, A., Krause, T. G., & The Danish Covid-19 Genome Consortium (2021). Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study. The Lancet Infectious Diseases, 21(11), 1507-1517. https://doi.org/10.1016/S1473-3099(21)00290-5

Vancouver

Bager P, Wohlfahrt J, Fonager J, Rasmussen M, Albertsen M, Michaelsen TY o.a. Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study. The Lancet Infectious Diseases. 2021;21(11):1507-1517. https://doi.org/10.1016/S1473-3099(21)00290-5

Author

Bager, Peter ; Wohlfahrt, Jan ; Fonager, Jannik ; Rasmussen, Morten ; Albertsen, Mads ; Michaelsen, Thomas Yssing ; Møller, Camilla Holten ; Ethelberg, Steen ; Legarth, Rebecca ; Button, Mia Sarah Fischer ; Gubbels, Sophie ; Voldstedlund, Marianne ; Mølbak, Kåre ; Skov, Robert Leo ; Fomsgaard, Anders ; Krause, Tyra Grove ; The Danish Covid-19 Genome Consortium. / Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark : an observational cohort study. I: The Lancet Infectious Diseases. 2021 ; Bind 21, Nr. 11. s. 1507-1517.

Bibtex

@article{198e4c8c832d40c7868b9df3f9c27233,
title = "Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study",
abstract = "Background: The more infectious SARS-CoV-2 lineage B.1.1.7 rapidly spread in Europe after December, 2020, and a concern that B.1.1.7 could cause more severe disease has been raised. Taking advantage of Denmark's high RT-PCR testing and whole genome sequencing capacities, we used national health register data to assess the risk of COVID-19 hospitalisation in individuals infected with B.1.1.7 compared with those with other SARS-CoV-2 lineages. Methods: We did an observational cohort study of all SARS-CoV-2-positive cases confirmed by RT-PCR in Denmark, sampled between Jan 1 and March 24, 2021, with 14 days of follow-up for COVID-19 hospitalisation. Cases were identified in the national COVID-19 surveillance system database, which includes data from the Danish Microbiology Database (RT-PCR test results), the Danish COVID-19 Genome Consortium, the National Patient Registry, the Civil Registration System, as well as other nationwide registers. Among all cases, COVID-19 hospitalisation was defined as first admission lasting longer than 12 h within 14 days of a sample with a positive RT-PCR result. The study population and main analysis were restricted to the proportion of cases with viral genome data. We calculated the risk ratio (RR) of admission according to infection with B.1.1.7 versus other co-existing lineages with a Poisson regression model with robust SEs, adjusted a priori for sex, age, calendar time, region, and comorbidities. The contribution of each covariate to confounding of the crude RR was evaluated afterwards by a stepwise forward inclusion. Findings: Between Jan 1 and March 24, 2021, 50 958 individuals with a positive SARS-CoV-2 test and at least 14 days of follow-up for hospitalisation were identified; 30 572 (60·0%) had genome data, of whom 10 544 (34·5%) were infected with B.1.1.7. 1944 (6·4%) individuals had a COVID-19 hospitalisation and of these, 571 (29·4%) had a B.1.1.7 infection and 1373 (70·6%) had an infection with other SARS-CoV-2 lineages. Although the overall number of hospitalisations decreased during the study period, the proportion of individuals infected with B.1.1.7 increased from 3·5% to 92·1% per week. B.1.1.7 was associated with a crude RR of hospital admission of 0·79 (95% CI 0·72–0·87; p<0·0001) and an adjusted RR of 1·42 (95% CI 1·25–1·60; p<0·0001). The adjusted RR was increased in all strata of age and calendar period—the two covariates with the largest contribution to confounding of the crude RR. Interpretation: Infection with SARS-CoV-2 lineage B.1.1.7 was associated with an increased risk of hospitalisation compared with that of other lineages in an analysis adjusted for covariates. The overall effect on hospitalisations in Denmark was lessened due to a strict lockdown, but our findings could support hospital preparedness and modelling of the projected impact of the epidemic in countries with uncontrolled spread of B.1.1.7. Funding: None.",
author = "Peter Bager and Jan Wohlfahrt and Jannik Fonager and Morten Rasmussen and Mads Albertsen and Michaelsen, {Thomas Yssing} and M{\o}ller, {Camilla Holten} and Steen Ethelberg and Rebecca Legarth and Button, {Mia Sarah Fischer} and Sophie Gubbels and Marianne Voldstedlund and K{\aa}re M{\o}lbak and Skov, {Robert Leo} and Anders Fomsgaard and Krause, {Tyra Grove} and {The Danish Covid-19 Genome Consortium}",
note = "Publisher Copyright: {\textcopyright} 2021 Elsevier Ltd",
year = "2021",
doi = "10.1016/S1473-3099(21)00290-5",
language = "English",
volume = "21",
pages = "1507--1517",
journal = "The Lancet Infectious Diseases",
issn = "1473-3099",
publisher = "TheLancet Publishing Group",
number = "11",

}

RIS

TY - JOUR

T1 - Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark

T2 - an observational cohort study

AU - Bager, Peter

AU - Wohlfahrt, Jan

AU - Fonager, Jannik

AU - Rasmussen, Morten

AU - Albertsen, Mads

AU - Michaelsen, Thomas Yssing

AU - Møller, Camilla Holten

AU - Ethelberg, Steen

AU - Legarth, Rebecca

AU - Button, Mia Sarah Fischer

AU - Gubbels, Sophie

AU - Voldstedlund, Marianne

AU - Mølbak, Kåre

AU - Skov, Robert Leo

AU - Fomsgaard, Anders

AU - Krause, Tyra Grove

AU - The Danish Covid-19 Genome Consortium

N1 - Publisher Copyright: © 2021 Elsevier Ltd

PY - 2021

Y1 - 2021

N2 - Background: The more infectious SARS-CoV-2 lineage B.1.1.7 rapidly spread in Europe after December, 2020, and a concern that B.1.1.7 could cause more severe disease has been raised. Taking advantage of Denmark's high RT-PCR testing and whole genome sequencing capacities, we used national health register data to assess the risk of COVID-19 hospitalisation in individuals infected with B.1.1.7 compared with those with other SARS-CoV-2 lineages. Methods: We did an observational cohort study of all SARS-CoV-2-positive cases confirmed by RT-PCR in Denmark, sampled between Jan 1 and March 24, 2021, with 14 days of follow-up for COVID-19 hospitalisation. Cases were identified in the national COVID-19 surveillance system database, which includes data from the Danish Microbiology Database (RT-PCR test results), the Danish COVID-19 Genome Consortium, the National Patient Registry, the Civil Registration System, as well as other nationwide registers. Among all cases, COVID-19 hospitalisation was defined as first admission lasting longer than 12 h within 14 days of a sample with a positive RT-PCR result. The study population and main analysis were restricted to the proportion of cases with viral genome data. We calculated the risk ratio (RR) of admission according to infection with B.1.1.7 versus other co-existing lineages with a Poisson regression model with robust SEs, adjusted a priori for sex, age, calendar time, region, and comorbidities. The contribution of each covariate to confounding of the crude RR was evaluated afterwards by a stepwise forward inclusion. Findings: Between Jan 1 and March 24, 2021, 50 958 individuals with a positive SARS-CoV-2 test and at least 14 days of follow-up for hospitalisation were identified; 30 572 (60·0%) had genome data, of whom 10 544 (34·5%) were infected with B.1.1.7. 1944 (6·4%) individuals had a COVID-19 hospitalisation and of these, 571 (29·4%) had a B.1.1.7 infection and 1373 (70·6%) had an infection with other SARS-CoV-2 lineages. Although the overall number of hospitalisations decreased during the study period, the proportion of individuals infected with B.1.1.7 increased from 3·5% to 92·1% per week. B.1.1.7 was associated with a crude RR of hospital admission of 0·79 (95% CI 0·72–0·87; p<0·0001) and an adjusted RR of 1·42 (95% CI 1·25–1·60; p<0·0001). The adjusted RR was increased in all strata of age and calendar period—the two covariates with the largest contribution to confounding of the crude RR. Interpretation: Infection with SARS-CoV-2 lineage B.1.1.7 was associated with an increased risk of hospitalisation compared with that of other lineages in an analysis adjusted for covariates. The overall effect on hospitalisations in Denmark was lessened due to a strict lockdown, but our findings could support hospital preparedness and modelling of the projected impact of the epidemic in countries with uncontrolled spread of B.1.1.7. Funding: None.

AB - Background: The more infectious SARS-CoV-2 lineage B.1.1.7 rapidly spread in Europe after December, 2020, and a concern that B.1.1.7 could cause more severe disease has been raised. Taking advantage of Denmark's high RT-PCR testing and whole genome sequencing capacities, we used national health register data to assess the risk of COVID-19 hospitalisation in individuals infected with B.1.1.7 compared with those with other SARS-CoV-2 lineages. Methods: We did an observational cohort study of all SARS-CoV-2-positive cases confirmed by RT-PCR in Denmark, sampled between Jan 1 and March 24, 2021, with 14 days of follow-up for COVID-19 hospitalisation. Cases were identified in the national COVID-19 surveillance system database, which includes data from the Danish Microbiology Database (RT-PCR test results), the Danish COVID-19 Genome Consortium, the National Patient Registry, the Civil Registration System, as well as other nationwide registers. Among all cases, COVID-19 hospitalisation was defined as first admission lasting longer than 12 h within 14 days of a sample with a positive RT-PCR result. The study population and main analysis were restricted to the proportion of cases with viral genome data. We calculated the risk ratio (RR) of admission according to infection with B.1.1.7 versus other co-existing lineages with a Poisson regression model with robust SEs, adjusted a priori for sex, age, calendar time, region, and comorbidities. The contribution of each covariate to confounding of the crude RR was evaluated afterwards by a stepwise forward inclusion. Findings: Between Jan 1 and March 24, 2021, 50 958 individuals with a positive SARS-CoV-2 test and at least 14 days of follow-up for hospitalisation were identified; 30 572 (60·0%) had genome data, of whom 10 544 (34·5%) were infected with B.1.1.7. 1944 (6·4%) individuals had a COVID-19 hospitalisation and of these, 571 (29·4%) had a B.1.1.7 infection and 1373 (70·6%) had an infection with other SARS-CoV-2 lineages. Although the overall number of hospitalisations decreased during the study period, the proportion of individuals infected with B.1.1.7 increased from 3·5% to 92·1% per week. B.1.1.7 was associated with a crude RR of hospital admission of 0·79 (95% CI 0·72–0·87; p<0·0001) and an adjusted RR of 1·42 (95% CI 1·25–1·60; p<0·0001). The adjusted RR was increased in all strata of age and calendar period—the two covariates with the largest contribution to confounding of the crude RR. Interpretation: Infection with SARS-CoV-2 lineage B.1.1.7 was associated with an increased risk of hospitalisation compared with that of other lineages in an analysis adjusted for covariates. The overall effect on hospitalisations in Denmark was lessened due to a strict lockdown, but our findings could support hospital preparedness and modelling of the projected impact of the epidemic in countries with uncontrolled spread of B.1.1.7. Funding: None.

U2 - 10.1016/S1473-3099(21)00290-5

DO - 10.1016/S1473-3099(21)00290-5

M3 - Journal article

C2 - 34171231

AN - SCOPUS:85117642711

VL - 21

SP - 1507

EP - 1517

JO - The Lancet Infectious Diseases

JF - The Lancet Infectious Diseases

SN - 1473-3099

IS - 11

ER -

ID: 284186877